COVID-19 Will Spur Decentralized and Hybrid Trials – Novartis Hails Digital Investment
Decentralized Trials Can Only Soften The Blow
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.
You may also be interested in...
Will Decentralized Trials Continue Growing After COVID-19 Pandemic Ends?
Some of the changes from the pandemic are here to stay, but so are some of the concerns that kept them from taking root.
Novartis Digital Strategy Dampens COVID-19 Impact
The Swiss major says operations have not faced significant disruptions from the coronavirus pandemic but recruitment of patients for new trials, including a high-profile trial of inclisiran, have been impacted.
CDER’s Woodcock On COVID-19: Missed User Fees Unlikely, But Some Work Will Be ‘Set Aside’
In a podcast interview, Janet Woodcock talks about review deadlines, prioritizing pre-approval inspections, and how advisory committees could be held in an era of social distancing.